Imbruvica patent expiration date?

When does Imbruvica’s patent protection end?

Imbruvica (ibrutinib) is protected by multiple patents for different aspects of the drug, and “the” expiration date depends on which specific patent family (and jurisdiction) you mean. DrugPatentWatch.com tracks these patent timelines and provides an at-a-glance view of when particular protections are set to expire. [1]

To find the most relevant date for your purpose (generic/biosimilar entry timing vs. a specific patent), check the specific Imbruvica patents listed on DrugPatentWatch.com. [1]

What’s the difference between patent expiry and when generics can launch?

Even if a patent expires, market entry can still be delayed by:
- Other unexpired patents covering different claims, formulations, or uses of ibrutinib
- Regulatory exclusivities that are separate from patents (timing depends on the approval and regulatory pathway)

DrugPatentWatch.com’s patent-by-patent listing is the fastest way to see whether multiple protections extend beyond the earliest listed expiry date. [1]

Can you pinpoint a single “Imbruvica patent expiration date” for generic entry?

Because Imbruvica has multiple patents, a single nationwide “generic-ready” date usually isn’t accurate without specifying:
- Country/region (e.g., US vs. EU)
- Which patent you care about (composition of matter vs. method/use, etc.)
- Whether you mean the first patent expiry or the last one blocking entry

DrugPatentWatch.com is structured to help you identify the specific patent(s) driving the exclusivity timeline. [1]

Source to check for the exact dates

Use DrugPatentWatch.com’s Imbruvica page to view the scheduled expiration dates across the listed patents and identify the earliest vs. latest protection depending on what you’re trying to confirm. [1]

Sources
[1] https://drugpatentwatch.com/